Rett syndrome is a rare neurological disorder that is more common among girls. The disorder affects brain development causing development disorders, loss of motor skills, and speech. Moreover, the disorder is recognized in a child between 6-18 months caused by mutations on the X-chromosome over a gene called MECP2. Rett syndrome can lead to a wide range of disabilities from mild to severe. The disorder is divided into four stages. Stage I: early-onset; stage II: rapid destruction; stage III: plateau; and stage IV: late motor deterioration. The mental growth of the child stops in the first stage of Rett syndrome. In the second stage of Rett syndrome, children usually lose the ability to perform skills. The third stage usually starts between 2 and 10 years of age. At this stage, children face problems with movement and behavior Stage IV is the last stage of Rett's syndrome and usually starts after 10 years of age and can last for decades or years. Common symptoms of rett syndrome include unusual eye movements, slow growth, agitation and irritation, poor language skills, hand movement problems, muscle and coordination issues, and breathing disorders.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the Rett syndrome market.
Top Impacting Factors
- Increase in incidence of genetic disorders across the world drives the market growth.
- Rise in female population worldwide will propel the market growth.
- Increase in degenerative nerve cells because of lifestyle alterations such as improper sleeping, unhealthy eating habits and high-stress levels and surge in number of innovations in neurodegenerative disease drug discovery accelerate the market growth.
- In addition, therapies in their clinical phases are being developed to treat severe symptoms for the Rett syndrome treatment which also provides an opportunistic growth in the market.
- Technological advancements for early diagnosis of these fatal diseases and increase in awareness increased awareness related to neurological disorders are expected to propel the market growth.
- Furthermore, rise in research and development activities to for the treatment of Rett syndrome, increase in healthcare expenditure, and improvement in healthcare infrastructure positively affect the market growth.
Market Trends
New Product Launches to Flourish the Market
In June 2018, AMO Pharma received orphan drug designation from the U.S Food and Drug Administration for AMO-04, a glutamate modulator for the treatment of rett syndrome. This designation is an important milestone for the development program of this syndrome and reinforces the critical need for a new treatment option for rett syndrome.
In October 2018, Anavex Life Sciences Corp. received the U.S Food and Drug Administration approval for phase ll trial of ANAVEX2-73 in patients with rett syndrome. ANAVEX2-73 has already received the orphan drug designation from the U.S FDA for the treatment of rett syndrome.
Key Benefits of the Report
- This study presents the analytical depiction of the Rett syndrome market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Rett Syndrome Market Report
- Which are the leading market players active in the Rett syndrome market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is Rett syndrome market?
- What is Rett syndrome market prediction in the future?
- Who are the leading global players in the Rett syndrome market?
- What are the current trends and predicted trends?
- What are the key benefits of the Rett syndrome market report?
Rett Syndrome Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Treatment |
|
 By End User |
|
 By Region |
|
 Key Market Players | AstraZeneca PLC, ASD Clinics, Eisai Inc, Abbott, Cincinnati Children's Hospital Medical Center, OT For Kids, Kid Sense Child Development Corporation Pty Ltd, Johnson & Johnson, GlaxoSmithKline Plc, Takeda Pharmaceuticals |
Loading Table Of Content...
